Jade Biosciences, Inc. (JBIO) Reports Preclinical Data on Anti-IFN-β Antibody JADE301
Jade Biosciences reported preclinical data for JADE301, a half-life-extended anti-IFN-β mAb for dermatomyositis, and expects to start a placebo-controlled, single ascending-dose Phase 1 study in Q4 2026 with interim data in H2 2027.Material DetailsContext by AI AnalystJBIO is early in development f…